Abstract
Since Virchow first proposed in 1863 that tumors could originate from sites of chronic inflammation, it has been well established that chronic inflammation both contributes to cancer progression and predisposes tissue to various types of cancer. Experimental, clinical, and epidemiological studies have all demonstrated the strong association between chronic inflammation and cancer, and many studies have correlated the prolonged presence of the inflammatory milieu with an increased risk for developing cancer. Proinflammatory cytokines, chemokines and adhesion molecules, which regulate the sequential recruitment of leukocytes, are frequently observed in tumor microenvironment. These early desmoplastic changes could stimulate fibroblasts and endothelial cell division and produce components for tissue remodeling and neovascularization, ultimately promoting neoplastic processes. In this review article we overview the current understanding of the role of chronic inflammation in neoangiogenesis, tumor initiation, promotion, and progression.
Keywords: Inflammation, microenvironment, neoangiogenesis, cancer
Current Pharmaceutical Design
Title: Inflammation, Microenvironment, and the Immune System in Cancer Progression
Volume: 15 Issue: 17
Author(s): Andrew Keibel, Vinod Singh and Mahesh C. Sharma
Affiliation:
Keywords: Inflammation, microenvironment, neoangiogenesis, cancer
Abstract: Since Virchow first proposed in 1863 that tumors could originate from sites of chronic inflammation, it has been well established that chronic inflammation both contributes to cancer progression and predisposes tissue to various types of cancer. Experimental, clinical, and epidemiological studies have all demonstrated the strong association between chronic inflammation and cancer, and many studies have correlated the prolonged presence of the inflammatory milieu with an increased risk for developing cancer. Proinflammatory cytokines, chemokines and adhesion molecules, which regulate the sequential recruitment of leukocytes, are frequently observed in tumor microenvironment. These early desmoplastic changes could stimulate fibroblasts and endothelial cell division and produce components for tissue remodeling and neovascularization, ultimately promoting neoplastic processes. In this review article we overview the current understanding of the role of chronic inflammation in neoangiogenesis, tumor initiation, promotion, and progression.
Export Options
About this article
Cite this article as:
Keibel Andrew, Singh Vinod and Sharma C. Mahesh, Inflammation, Microenvironment, and the Immune System in Cancer Progression, Current Pharmaceutical Design 2009; 15 (17) . https://dx.doi.org/10.2174/138161209788453167
DOI https://dx.doi.org/10.2174/138161209788453167 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Elucidating Molecular Interactions of Ten Natural Compounds Targeting E6 HPV High Risk Oncoproteins Using Microsecond Molecular Dynamics Simulations
Medicinal Chemistry Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics Tumor Immune Escape Mechanisms that Operate During Metastasis
Current Pharmaceutical Biotechnology Transmission and Immunopathogenesis of FIV in Cats as a Model for HIV
Current HIV Research Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Antiviral Effects of Saffron and its Major Ingredients
Current Drug Delivery Coexistence of Type-1 Diabetes Mellitus and Papillary Thyroid Carcinoma
Current Diabetes Reviews A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours
Current Drug Delivery Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Cryptotanshinone Induces Pro-death Autophagy through JNK Signaling Mediated by Reactive Oxygen Species Generation in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Branched Disulfide-Based Polyamidoamines Capable of Mediating High Gene Transfection
Current Pharmaceutical Design Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry Medullary Thyroid Cancer: New Targeted Molecular Therapies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Therapeutic Potential of Mucoadhesive Drug Delivery Systems - An Updated Patent Review
Recent Patents on Drug Delivery & Formulation Trypsin-Chymotrypsin Inhibitors from Vigna mungo Seeds
Protein & Peptide Letters Engineered Silver Nanoparticles, A New Nanoweapon Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Tracking Cell Signaling Protein Expression and Phosphorylation by Innovative Proteomic Solutions
Current Pharmaceutical Biotechnology Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation Destabilizing Aneuploidy by Targeting Cell Cycle and Mitotic Checkpoint Proteins in Cancer Cells
Current Drug Targets Synthesis and in vitro Anti-tumor Activity of Some New Sebacoyl Chloride Based Heterocycles
Current Organic Synthesis